Breast cancer represents a highly heterogeneous malignancy, in which three principal biomarkers, the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), play a central role in molecular classification and therapeutic strategies guidance [11]. Here, ERBB2 is linked to breast carcinoma.